FLT3 and leukemia: Li et al. found that the FLT3 inhibitor gilteritinib induces the expression of NKG2DL on leukemia cells and constructed an AND-gate NKG2d/FLT3 dual CAR to target FLT3-mutated cells, which eradicated leukemia in a mouse model [91].